表紙:脊髄性筋萎縮症 (SMA) 治療の世界市場:産業分析・規模・シェア・成長率・動向・予測
市場調査レポート
商品コード
838363

脊髄性筋萎縮症 (SMA) 治療の世界市場:産業分析・規模・シェア・成長率・動向・予測

Global Spinal Muscular Atrophy (SMA) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2019 to 2026

出版日: | 発行: Value Market Research | ページ情報: 英文 100 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=130.29円
脊髄性筋萎縮症 (SMA) 治療の世界市場:産業分析・規模・シェア・成長率・動向・予測
出版日: 2019年11月01日
発行: Value Market Research
ページ情報: 英文 100 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の脊髄性筋萎縮症 (SMA) 市場を調査し、市場の定義と概要、バリューチェーン、市場成長への各種影響因子および市場機会の分析、タイプ・治療法・投与経路・地域別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場分析

  • イントロダクション
  • バリューチェーン分析
  • 成長推進因子
  • 成長抑制因子
  • 市場機会
  • ポーターのファイブフォース分析

第4章 脊髄性筋萎縮症 (SMA) 治療市場の分析:タイプ別

  • タイプ1
  • タイプ2
  • タイプ3
  • タイプ4

第5章 脊髄性筋萎縮症 (SMA) 治療市場の分析:治療法別

  • 遺伝子療法
  • 薬物療法

第6章 脊髄性筋萎縮症 (SMA) 治療市場の分析:投与経路別

  • 経口投与
  • くも膜下投与

第7章 脊髄性筋萎縮症 (SMA) 治療市場の分析:地域別

  • 北米
  • 北米市場の推計
  • 北米市場の推計:国別
    • 米国
    • カナダ
  • 欧州 (EU)
  • 欧州 (EU)市場の推計
  • 欧州 (EU)市場の推計:国別
    • 英国
    • ドイツ
    • フランス
    • その他
  • アジア太平洋
  • アジア太平洋市場の推計
  • アジア太平洋市場の推計:国別
    • 中国
    • 日本
    • インド
    • その他
  • ラテンアメリカ
  • ラテンアメリカ市場の推計
  • ラテンアメリカ市場の推計:国別
    • ブラジル
    • その他
  • 中東・アフリカ
  • 中東・アフリカ市場の推計
  • 中東・アフリカ市場の推計:国別
  • 中東
  • アフリカ

第8章 競合環境

  • 市場競合
  • 提携・協力・合意
  • M&A
  • 新製品の開発
  • その他

第9章 企業プロファイル

  • Avexis, Inc.
  • Biogen
  • Cytokinetics, Inc.
  • F. Hoffmann - La Roche Ltd
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Tentative TOC
目次

Value Market Research's latest report on the Global Spinal Muscular Atrophy (SMA) Treatment Market identified a significant growth in the industry over the last few years and anticipates it to grow considerably within the forecast period of 2020-2026.

The global spinal muscular atrophy (sma) treatment market report provides a complete evaluation of the market for the forecast period. The report consists of various segments as well as an analysis of the factors playing a significant role in the market. The factors include the drivers, restraints, challenges and opportunities and the impact of these factors on the market has been provided in the report. The drivers and restraints are classified as intrinsic factors while the opportunities and challenges are classified as extrinsic factors of the market. The global spinal muscular atrophy (sma) treatment market study provides an insight on the developments of the market in terms of revenue throughout the specified period.

This report provides a complete analysis for the global spinal muscular atrophy (sma) treatment market. An in-depth secondary research, primary interviews and in-house expert reviews are responsible for providing the market estimates for the global spinal muscular atrophy (sma) treatment market. These market estimates have been put together by studying the impact of different social, political and economic factors along with the current market dynamics that are affecting the global spinal muscular atrophy (sma) treatment market growth.

The report begins with the market overview, followed by a crisp executive summary. The Porter's Five Forces analysis covered in this study will assist in understanding the five forces namely buyers bargaining power, suppliers bargaining power, threat of new entrants, the threat of substitutes and the degree of competition in the global spinal muscular atrophy (sma) treatment market. It also helps to explain the various participants such as system integrators, intermediaries and end users within the market. The report by Value Market Research also focuses on the competitive landscape of the global spinal muscular atrophy (sma) treatment market.

The market analysis involves a section exclusively to list the major players of the global spinal muscular atrophy (sma) treatment market wherein our analysts provide an insight into the financial statements of all the key players along with its key development product. The company profile section in the report also provides a business overview and financial information. The companies provided in this section can be customized as per the client's requirement.

The Spinal Muscular Atrophy (SMA) Treatment Market Report Segments the market as below -

  • By Type
    • Type 1
    • Type 2
    • Type 3
    • Type 4
  • By Treatment
    • Gene Therapy
    • Drug
    • By Route Of Administration
    • Oral
    • Intrathecal

TABLE OF CONTENT

1 PREFACE

  • 1.1. REPORT DESCRIPTION
    • 1.1.1. OBJECTIVE
    • 1.1.2. TARGET AUDIENCE
    • 1.1.3. UNIQUE SELLING PROPOSITION (USP) & OFFERINGS
  • 1.2. RESEARCH SCOPE
  • 1.3. RESEARCH METHODOLOGY
    • 1.3.1. MARKET RESEARCH PROCESS
    • 1.3.2. MARKET RESEARCH METHODOLOGY
      • 1.3.2.1. SECONDARY RESEARCH
      • 1.3.2.2. PRIMARY RESEARCH
      • 1.3.2.3. MODELS

2 EXECUTIVE SUMMARY

  • 2.1. MARKET HIGHLIGHTS
  • 2.2. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: SNAPSHOT

3 SPINAL MUSCULAR ATROPHY (SMA) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. INTRODUCTION
  • 3.2. MARKET DRIVERS
    • 3.2.1. DRIVER 1
    • 3.2.2. DRIVER 2
  • 3.3. MARKET RESTRAINTS
    • 3.3.1. RESTRAINT 1
    • 3.3.2. RESTRAINT 2
  • 3.4. OPPORTUNITIES
    • 3.4.1. OPPORTUNITY 1
  • 3.5. TRENDS
    • 3.5.1. TREND 1
    • 3.5.2. TREND 2
  • 3.6. PORTER'S FIVE FORCE ANALYSIS
  • 3.7. SPINAL MUSCULAR ATROPHY (SMA) TREATMENT: MARKET ATTRACTIVENESS ANALYSIS
    • 3.7.1. MARKET ATTRACTIVE ANALYSIS BY TYPE
    • 3.7.2. MARKET ATTRACTIVE ANALYSIS BY TREATMENT
    • 3.7.3. MARKET ATTRACTIVE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 3.7.4. MARKET ATTRACTIVE ANALYSIS BY REGION

4 VALUE CHAIN ANALYSIS

  • 4.1. SPINAL MUSCULAR ATROPHY (SMA) TREATMENT: VALUE CHAIN ANALYSIS
  • 4.2. SPINAL MUSCULAR ATROPHY (SMA) TREATMENT RAW MATERIAL ANALYSIS
    • 4.2.1. LIST OF RAW MATERIALS
    • 4.2.2. SPINAL MUSCULAR ATROPHY (SMA) TREATMENT RAW MATERIAL MANUFACTURES LIST
    • 4.2.3. PRICE TREND OF SPINAL MUSCULAR ATROPHY (SMA) TREATMENT KEY RAW MATERIALS
  • 4.3. LIST OF POTENTIAL BUYERS
  • 4.4. MARKETING CHANNEL
    • 4.4.1. DIRECT MARKETING
    • 4.4.2. INDIRECT MARKETING
    • 4.4.3. MARKETING CHANNEL DEVELOPMENT TREND

5 GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE

  • 5.1. OVERVIEW BY TYPE
  • 5.2. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE
  • 5.3. TYPE 1
    • 5.3.1. OVERVIEW
  • 5.4. TYPE 2
    • 5.4.1. OVERVIEW
  • 5.5. TYPE 3
    • 5.5.1. OVERVIEW
  • 5.6. TYPE 4
    • 5.6.1. OVERVIEW

6 GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TREATMENT

  • 6.1. OVERVIEW BY TREATMENT
  • 6.2. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TREATMENT
  • 6.3. GENE THERAPY
    • 6.3.1. OVERVIEW
  • 6.4. DRUG
    • 6.4.1. OVERVIEW

7 GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. OVERVIEW BY ROUTE OF ADMINISTRATION
  • 7.2. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  • 7.3. ORAL
    • 7.3.1. OVERVIEW
  • 7.4. INTRATHECAL
    • 7.4.1. OVERVIEW

8 GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. REGIONAL OUTLOOK
  • 8.2. INTRODUCTION
  • 8.3. NORTH AMERICA
    • 8.3.1. OVERVIEW
    • 8.3.2. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY MARKET SEGMENT
    • SOURCE: SECONDARY RESEARCH, EXPERTISE INTERVIEW, AND VMR ANALYSIS 48
    • 8.3.3. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY
    • 8.3.4. UNITED STATE
    • 8.3.5. REST OF NORTH AMERICA
  • 8.4. EUROPE
    • 8.4.1. OVERVIEW
    • 8.4.2. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY MARKET SEGMENT
    • 8.4.3. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY
    • 8.4.4. UNITED KINGDOM
    • 8.4.5. FRANCE
    • 8.4.6. GERMANY
    • 8.4.7. REST OF EUROPE
  • 8.5. ASIA PACIFIC
    • 8.5.1. OVERVIEW
    • 8.5.2. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY MARKET SEGMENT
    • 8.5.3. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY
    • 8.5.4. CHINA
    • 8.5.5. JAPAN
    • 8.5.6. INDIA
    • 8.5.7. REST OF ASIA PACIFIC
  • 8.6. LATIN AMERICA
    • 8.6.1. OVERVIEW
    • 8.6.2. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY MARKET SEGMENT
    • 8.6.3. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY
    • 8.6.4. BRAZIL
    • 8.6.5. REST OF LATIN AMERICA
  • 8.7. MIDDLE EAST & AFRICA
    • 8.7.1. OVERVIEW
    • 8.7.2. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY MARKET SEGMENT
    • 8.7.3. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY
    • 8.7.4. MIDDLE EAST
    • 8.7.5. AFRICA

9 COMPETITIVE LANDSCAPE OF THE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT COMPANIES

  • 9.1. SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET COMPETITION
  • 9.2. PARTNERSHIP/COLLABORATION/AGREEMENT
  • 9.3. MERGER AND ACQUISITIONS
  • 9.4. NEW PRODUCT LAUNCH
  • 9.5. OTHER DEVELOPMENTS

10 COMPANY PROFILES OF SPINAL MUSCULAR ATROPHY (SMA) TREATMENT INDUSTRY

  • 10.1. COMPANY SHARE ANALYSIS
  • 10.2. MARKET CONCENTRATION RATE
  • 10.3. AVEXIS, INC.
    • 10.3.1. COMPANY OVERVIEW:
    • 10.3.2. FINANCIALS:
    • 10.3.3. PRODUCTS:
    • 10.3.4. RECENT DEVELOPMENTS:
  • 10.4. BIOGEN
    • 10.4.1. COMPANY OVERVIEW:
    • 10.4.2. FINANCIALS:
    • 10.4.3. PRODUCTS:
    • 10.4.4. RECENT DEVELOPMENTS:
  • 10.5. CYTOKINETICS INC.
    • 10.5.1. COMPANY OVERVIEW:
    • 10.5.2. FINANCIALS:
    • 10.5.3. PRODUCTS:
    • 10.5.4. RECENT DEVELOPMENTS:
  • 10.6. F. HOFFMANN - LA ROCHE LTD
    • 10.6.1. COMPANY OVERVIEW:
    • 10.6.2. FINANCIALS:
    • 10.6.3. PRODUCTS:
    • 10.6.4. RECENT DEVELOPMENTS:
  • 10.7. IONIS PHARMACEUTICALS INC.
    • 10.7.1. COMPANY OVERVIEW:
    • 10.7.2. FINANCIALS:
    • 10.7.3. PRODUCTS:
    • 10.7.4. RECENT DEVELOPMENTS:
  • 10.8. NOVARTIS AG
    • 10.8.1. COMPANY OVERVIEW:
    • 10.8.2. FINANCIALS:
    • 10.8.3. PRODUCTS:
    • 10.8.4. RECENT DEVELOPMENTS:

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • TABLE 1. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: SNAPSHOT
  • TABLE 2. DRIVERS OF THE GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: IMPACT ANALYSIS
  • TABLE 3. RESTRAINTS OF THE GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: IMPACT ANALYSIS
  • TABLE 4. LIST OF RAW MATERIAL
  • TABLE 5. LIST OF RAW MATERIAL MANUFACTURES
  • TABLE 6. LIST OF POTENTIAL BUYERS
  • TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 1 BY GEOGRAPHY (USD MN)
  • TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 2 BY GEOGRAPHY (USD MN)
  • TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 3 BY GEOGRAPHY (USD MN)
  • TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 4 BY GEOGRAPHY (USD MN)
  • TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TREATMENT (USD MN)
  • TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN GENE THERAPY BY GEOGRAPHY (USD MN)
  • TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN DRUG BY GEOGRAPHY (USD MN)
  • TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN ORAL BY GEOGRAPHY (USD MN)
  • TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN INTRATHECAL BY GEOGRAPHY (USD MN)
  • TABLE 18. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY GEOGRAPHY (USD MN)
  • TABLE 19. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 20. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 21. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 22. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 23. UNITED STATE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 24. UNITED STATE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 25. UNITED STATE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 26. REST OF NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 27. REST OF NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT(USD MN)
  • TABLE 28. REST OF NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION(USD MN)
  • TABLE 29. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 30. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 31. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 32. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 33. UNITED KINGDOM SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 34. UNITED KINGDOM SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 35. UNITED KINGDOM SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 36. FRANCE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 37. FRANCE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 38. FRANCE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 39. GERMANY SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 40. GERMANY SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 41. GERMANY SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 42. REST OF EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 43. REST OF EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 44. REST OF EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 45. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 46. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 47. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 48. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 49. CHINA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 50. CHINA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 51. CHINA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 52. JAPAN SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 53. JAPAN SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 54. JAPAN SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 55. INDIA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 56. INDIA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 57. INDIA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 58. REST OF ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 59. REST OF ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 60. REST OF ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 61. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 62. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 63. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 64. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 65. BRAZIL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 66. BRAZIL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 67. BRAZIL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 68. REST OF LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 69. REST OF LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 70. REST OF LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 71. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 72. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 73. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 74. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 75. MIDDLE EAST SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 76. MIDDLE EAST SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 77. MIDDLE EAST SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 78. AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • TABLE 79. AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ESTIMATE BY TREATMENT (USD MN)
  • TABLE 80. AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • TABLE 81. PARTNERSHIP/COLLABORATION/AGREEMENT
  • TABLE 82. MERGERS AND ACQUISITON
  • TABLE 83. NEW PRODUCT LAUNCH
  • TABLE 84. OTHER DEVELOPMENTS
  • TABLE 85. COMPANY MARKET SHARE ANALYSIS, 2018
  • TABLE 86. FINANCIAL HIGHLIGHTS
  • TABLE 87. MAJOR PRODUCTS
  • TABLE 88. FINANCIAL HIGHLIGHTS
  • TABLE 89. MAJOR PRODUCTS
  • TABLE 90. FINANCIAL HIGHLIGHTS
  • TABLE 91. MAJOR PRODUCTS
  • TABLE 92. FINANCIAL HIGHLIGHTS
  • TABLE 93. MAJOR PRODUCTS
  • TABLE 94. FINANCIAL HIGHLIGHTS
  • TABLE 95. MAJOR PRODUCTS
  • TABLE 96. FINANCIAL HIGHLIGHTS
  • TABLE 97. MAJOR PRODUCTS

LIST OF FIGURES

  • FIG. 1. RESEARCH SCOPE OF SPINAL MUSCULAR ATROPHY (SMA) TREATMENT REPORT
  • FIG. 1. MARKET RESEARCH PROCESS
  • FIG. 2. MARKET RESEARCH METHODOLOGY
  • FIG. 3. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET SIZE, BY REGION (USD MN)
  • FIG. 4. PORTERS FIVE FORCES ANALYSIS
  • FIG. 5. MARKET ATTRACTIVENESS ANALYSIS BY TYPE
  • FIG. 6. MARKET ATTRACTIVENESS ANALYSIS BY TREATMENT
  • FIG. 7. MARKET ATTRACTIVENESS ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIG. 8. MARKET ATTRACTIVENESS ANALYSIS BY REGION
  • FIG. 9. VALUE CHAIN ANALYSIS
  • FIG. 10. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TYPE (USD MN)
  • FIG. 11. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 1 BY REGION
  • FIG. 12. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 2 BY REGION
  • FIG. 13. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 3 BY REGION
  • FIG. 14. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN TYPE 4 BY REGION
  • FIG. 15. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY TREATMENT (USD MN)
  • FIG. 16. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN GENE THERAPY BY REGION
  • FIG. 17. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN DRUG BY REGION
  • FIG. 18. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION (USD MN)
  • FIG. 19. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN ORAL BY REGION
  • FIG. 20. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET ANALYSIS IN INTRATHECAL BY REGION
  • FIG. 21. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY REVENUE
  • FIG. 22. NORTH AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY REVENUE
  • FIG. 23. EUROPE SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY REVENUE
  • FIG. 24. ASIA PACIFIC SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY REVENUE
  • FIG. 25. LATIN AMERICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY REVENUE
  • FIG. 26. MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET BY REVENUE
  • FIG. 27. RECENT DEVELOPMENT IN SPINAL MUSCULAR ATROPHY (SMA) TREATMENT INDUSTRY
  • FIG. 28. COMPANY MARKET SHARE ANALYSIS, 2018